No, it was mentioned in the first study and not Data Confirmation. Bruh, if you are questioning the technology but it seem like you just invested for the COVID-19 screening and not ResAppDx since you seem to know very little about ResAppDx then it's time to sell or do more due diligence on ResAppDx which is RAP's core product.
Response No-vote letter update, page-42
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
